Stockreport

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event [Yahoo! Finance]

ALX Oncology Holdings Inc.  (ALXO) 
PDF Advancing novel EGFR-targeted antibody-drug conjugate (ADC) candidate, ALX2004, into clinical-stage development with IND submission planned for Q1 2025 Company implem [Read more]